Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6767MR)

This product GTTS-WQ6767MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6767MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7577MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ6238MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ3969MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ5116MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ14801MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ1667MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ4550MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ9081MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW